Stockscreener 앱 받기
259.89
1.17%
2.88
Insulet Corporation 주식(PODD)의 최신 뉴스
UPC Court of Appeal reverses Milan decision in Insulet v EOFlow dispute - MLex
Curious about Insulet (PODD) Q1 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
Investing in Insulet (NASDAQ:PODD) a year ago would have delivered you a 47% gain - simplywall.st
Insulet Corp. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Insulet forgoes high trade secret damages award in favour of injunction - IAM Patent
Wolfe Research Downgrades Insulet (BIT:1PODD) - Nasdaq
Insulet (PODD) Price Target Raised by Barclays Amid Leadership C - GuruFocus
Wolfe Research Downgrades Insulet (BMV:PODD) - Nasdaq
Here's What to Expect From Insulet's Next Earnings Report - MSN
Insulet stock gains on leadership change and strong outlook By Investing.com - Investing.com Canada
Canaccord maintains Buy on Insulet stock, price target at $324 - Investing.com
Insulet stock gains on leadership change and strong outlook - Investing.com
Insulet Shares Fall After Wolfe Research Downgrade - marketscreener.com
Insulet earns insulin patch pump patent victory against EOFlow with permanent injunction - MassDevice
Hologic Adds Wayde McMillan to its Board of Directors - Medical Product Outsourcing
Canaccord maintains Buy on Insulet stock, price target at $324 By Investing.com - Investing.com India
William Blair Reiterates Outperform Rating on Insulet Corporation (PODD) - StreetInsider
This Saia Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Canaccord Genuity Reiterates Buy Rating on Insulet Corporation (PODD) - StreetInsider
Wolfe Research Downgrades Insulet to Peer Perform From Outperform - marketscreener.com
Insulet names new CEO, plans to lift full year guidance - MSN
Insulin pump maker Insulet names J&J veteran as new CEO, replacing Hollingshead - The Business Journals
Analysts See Insulet’s Appointment Of Ashley McEvoy As CEO As A Positive Move - insights.citeline.com
Insulet Names New CEO, Expects to Top Revenue Projections - MSN
Insulet Appoints Ashley McEvoy as New CEO - TipRanks
Insulet (PODD) Welcomes Ashley McEvoy as New CEO, Gains Positive - GuruFocus
Insulet Earnings: What To Look For From PODD - Barchart.com
Ashley McEvoy named Insulet CEO - Yahoo Finance
Here's What To Expect From Insulet's Next Earnings Report - Barchart.com
Insulet (PODD) Appoints New CEO and Expects Revenue Surge - GuruFocus
Ashley McEvoy named president and CEO at Insulet - MassDevice
Insulet Appoints Ashley McEvoy President and CEO | PODD Stock Ne - GuruFocus
Insulet (PODD) Appoints Ashley McEvoy as New CEO | PODD Stock Ne - GuruFocus
Insulet Appoints Ashley McEvoy President And CEO - marketscreener.com
Insulet Appoints Ashley McEvoy President and CEO - Business Wire
Insulet's $452M Trade Secrets Award Reduced To $59.4M - Law360
Insulet Wins Worldwide Trade Secrets Injunction, Award Slashed - Bloomberg Law News
Automated Insulin Delivery System Market Is Booming Worldwide - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Insulet Corp (PODD) Stock Price Up 5.81% on Apr 24 - GuruFocus
Insulet (NASDAQ:PODD) Might Have The Makings Of A Multi-Bagger - Yahoo Finance
Insulet Corp. stock rises Wednesday, still underperforms market - MarketWatch
$100 Invested In Insulet 15 Years Ago Would Be Worth This Much Today - Benzinga
Insulet Corp (PODD) Shares Up 3.14% on Apr 22 - GuruFocus
Study Data Show Significant Glycemic Improvements With Omnipod 5 - Medical Product Outsourcing
RBC Cuts Price Target on Insulet to $325 From $340, Keeps Outperform Rating - marketscreener.com
What's Driving the Market Sentiment Around Insulet? - Benzinga
Insulet Announces Proposal for Upcoming Financing Deals - The Healthcare Technology Report.
Schroder Investment Management Group Decreases Stake in Insulet Co. (NASDAQ:PODD) - MarketBeat
Insider Sell: Insulet - marketscreener.com
BD, Teleflex, Insulet, UFP Technologies, and Haemonetics Shares Are Falling, What You Need To Know - Yahoo Finance
Strength Seen in Insulet (PODD): Can Its 7.2% Jump Turn into More Strength? - Nasdaq
Insulet's Market Expansion: The Omnipod Impact on Diabetes Care - marketscreener.com
Insulet's $389 Million Trading Day Lands 450th in Market Rankings - AInvest
Ex-Insulet CTO Mark Field has a new job in medtech with ITJ - Medical Design & Outsourcing
PODD Stock Benefits From the Launch of Omnipod 5 in Canada - MSN
12.05%
0.02%
자본화:
|
볼륨(24시간):